| Budget Amount *help |
¥23,920,000 (Direct Cost: ¥18,400,000、Indirect Cost: ¥5,520,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2015: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥13,910,000 (Direct Cost: ¥10,700,000、Indirect Cost: ¥3,210,000)
|
|---|
| Outline of Final Research Achievements |
An aortic aneurysm (AA) develops as a result of atherosclerosis and chronic inflammation. Surgical repair of AA is effective treatment to prevent rupture. However, the surgical procedures for thoracic and thoracoabdominal AA are extremely invasive and associated with high mortality and morbidity. We have reported that intravenous injection of mesenchymal stem cells (MSCs) could reduce the morbidity rate of aortic aneurysm by anti-inflammatory and tissue repair properties of MSCs. In this study, echographic measurements showed that the maximum aortic diameters of MSC-treated mice were significantly shorter than saline injection throughout 1 week after injection. In addition we demonstrated that the therapeutic mechanism of MSC-mediated AA regression contributed to regulation of the NF-kB, STAT, Smad3 and Akt signaling pathways, MSC-derived exosomes, and microRNAs secreted from MSC.
|
